Active Ingredient(s): Sulfinpyrazone
FDA Approved: * May 13, 1959
Pharm Company: * NOVARTIS
Category: Gout

Sulfinpyrazone is a uricosuric medication used to treat gout. It also sometimes is used to reduce platelet aggregation by inhibiting degranulation of platelets which reduces the release of ADP and thromboxane. Like other uricosurics, sulfinpyrazone works by competitively inhibiting uric acid reabsorption in the proximal tubule of the kidney. Contraindications Sulfinpyrazone must not be used in persons with renal impairment or a history of uric acid kidney stones.[1] Re... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.